文献速递肝病

miR-132通过协同多靶点抑制诱导肝脂肪变性和高脂血症

miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression.
PubMed 文献 · Gut · 2017-04-05

该研究在过表达miR-132的转基因小鼠、NAFLD患者肝组织及多种肝脂肪变小鼠模型中量化脂肪肝参数与miR-132及其靶点水平,并通过注射反义寡核苷酸抑制miR-132或其靶基因验证因果关系。结果发现过表达miR-132小鼠出现严重脂肪肝表型及血脂异常,而抑制miR-132可逆转饮食诱导肥胖小鼠的高脂血症表型。

要点

  • 过表达miR-132转基因小鼠出现严重脂肪肝表型、体重增加及血脂异常。
  • NAFLD患者和肝脂肪变/NASH小鼠模型中miR-132水平显著升高。
  • 抑制miR-132可逆转饮食诱导肥胖小鼠的高脂血症表型,而抑制单个靶点不能。

核心结论

  • miR-132是肝脏脂质稳态的关键调节因子,通过抑制多个靶点以情境依赖方式发挥累积协同效应。
  • 降低miR-132水平可能是肝脂肪变的潜在治疗方法。

研究设计与样本

  • 研究在过表达miR-132的新型转基因小鼠、NAFLD患者肝组织及多种肝脂肪变小鼠模型中量化脂肪肝参数和miR-132及其靶点水平。
  • 通过向饮食诱导肥胖小鼠注射抑制miR-132或其靶基因的反义寡核苷酸,验证miR-132过量的因果性。

主要发现

  • 过表达miR-132转基因小鼠表现出严重脂肪肝表型、体重增加、血清LDL/VLDL和肝脏甘油三酯升高,伴随已验证miR-132靶点减少及脂肪生成和脂质积累相关转录本增加。
  • 与对照相比,NAFLD患者和肝脂肪变或NASH小鼠模型的肝样本中miR-132显著增加,miR-132靶点不同程度减少。
  • 向饮食诱导肥胖小鼠注射抗miR-132寡核苷酸而非抑制其单个靶点,可逆转肝脏miR-132过量和高脂血症表型。

临床怎么用

  • 作者认为降低miR-132水平可能是肝脂肪变的一种治疗方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Both non-alcoholic fatty liver disease (NAFLD) and the multitarget complexity of microRNA (miR) suppression have recently raised much interest, but the in vivo impact and context-dependence of hepatic miR-target interactions are incompletely understood. Assessing the relative in vivo contributions of specific targets to miR-mediated phenotypes is pivotal for investigating metabolic processes. DESIGN: We quantified fatty liver parameters and the levels of miR-132 and its targets in novel transgenic mice overexpressing miR-132, in liver tissues from patients with NAFLD, and in diverse mouse models of hepatic steatosis. We tested the causal nature of miR-132 excess in these phenotypes by injecting diet-induced obese mice with antisense oligonucleotide suppressors of miR-132 or its target genes, and measured changes in metabolic parameters and transcripts. RESULTS: Transgenic mice overexpressing miR-132 showed a severe fatty liver phenotype and increased body weight, serum low-density lipoprotein/very low-density lipoprotein (LDL/VLDL) and liver triglycerides, accompanied by decreases in validated miR-132 targets and increases in lipogenesis and lipid accumulation-related transcripts. Likewise, liver samples from both patients with NAFLD and mouse models of hepatic steatosis or non-alcoholic steatohepatitis (NASH) displayed dramatic increases in miR-132 and varying decreases in miR-132 targets compared with controls. Furthermore, injecting diet-induced obese mice with anti-miR-132 oligonucleotides, but not suppressing its individual targets, reversed the hepatic miR-132 excess and hyperlipidemic phenotype. CONCLUSIONS: Our findings identify miR-132 as a key regulator of hepatic lipid homeostasis, functioning in a context-dependent fashion via suppression of multiple targets and with cumulative synergistic effects. This indicates reduction of miR-132 levels as a possible treatment of hepatic steatosis.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Hanin G, Yayon N, Tzur Y, et al. miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression. Gut. 2017. PMID: 28381526. doi:10.1136/gutjnl-2016-312869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。